US equities
|
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
META
$630.56
▼-1.88%
NVDA
$216.00
▲+2.39%
AAPL
$343.91
▼-1.10%
SPCX
$146.90
▼-0.40%
MSFT
$532.60
▲+1.54%
AMD
$531.28
▲+2.80%
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
META
$630.56
▼-1.88%
NVDA
$216.00
▲+2.39%
AAPL
$343.91
▼-1.10%
SPCX
$146.90
▼-0.40%
MSFT
$532.60
▲+1.54%
AMD
$531.28
▲+2.80%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Arcturus Therapeutics Holdings Inc
(NQ:
ARCT
)
9.910
+0.070 (+0.71%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcturus Therapeutics Holdings Inc
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 21, 2022
From
Arcturus Therapeutics
Via
Business Wire
65 Biggest Movers From Yesterday
↗
January 19, 2022
Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and...
Via
Benzinga
Expert Ratings For Arcturus Therapeutics
↗
August 31, 2021
Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed ...
Via
Benzinga
Analyst Ratings For Arcturus Therapeutics
↗
August 25, 2021
Analysts have provided the following ratings for Arcturus Therapeutics (NASDAQ:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
January 18, 2022
Gainers Brickell Biotech (NASDAQ:BBI) shares moved upwards by 71.1% to $0.36 during Tuesday's regular session. Brickell Biotech's stock is trading at a volume of...
Via
Benzinga
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 17, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs
↗
December 16, 2021
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) announced new data and updates from clinical development programs for ARCT-154 and ARCT-165, its self-amplifying...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
December 16, 2021
Gainers Calliditas Therapeutics (NASDAQ:CALT...
Via
Benzinga
58 Biggest Movers From Yesterday
↗
December 17, 2021
Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price...
Via
Benzinga
31 Stocks Moving In Thursday's Mid-Day Session
↗
December 16, 2021
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce...
Via
Benzinga
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
December 16, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
December 13, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
November 22, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 18, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
November 08, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
October 25, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
92 Biggest Movers From Friday
↗
November 08, 2021
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the...
Via
Benzinga
Arcturus Therapeutics Announces Leadership Appointments
October 21, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 20, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
October 12, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
↗
October 06, 2021
Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal...
Via
Benzinga
Arcturus Therapeutics Stock Sees Relative Strength Rating Rise To 83
↗
September 29, 2021
Arcturus Therapeutics sees its Relative Strength Rating hit the 80-plus level.
Via
Investor's Business Daily
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
September 22, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Vietnam's Health Ministry Approves Phase 2, Phase 3 Cohorts Of Arcturus' COVID-19 Vaccine Trial
↗
September 22, 2021
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has completed dosing of 100 subjects for the Phase 1 portion of the ARCT-154 Phase 1/2/3 trial, which consisted...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
↗
September 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...
Via
Benzinga
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
September 22, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Earnings Perspective: Return On Capital Employed
↗
September 15, 2021
According to Benzinga Pro data, during Q2, Arcturus Therapeutics (NASDAQ:ARCT) posted sales of $2.00 million. Earnings were up 6.84%, but Arcturus Therapeutics still reported an...
Via
Benzinga
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
September 08, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
September 07, 2021
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Mid-Day Market Update: ExOne Rises Following Acquisition News; LifeStance Health Shares Plummet
↗
August 12, 2021
Midway through trading Thursday, the Dow traded down 0.32% to 35,369.96 while the NASDAQ rose 0.01% to 14,766.11. The S&P also fell, dropping 0.10% to 4,443.23. The U.S. has...
Via
Benzinga
Topics
Stocks
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
